Navigation Links
Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer
Date:12/10/2009

WILMINGTON, Del., Dec. 10 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced that data from a Phase III study of postmenopausal women with hormone receptor-positive advanced breast cancer presented at the San Antonio Breast Cancer Symposium (Abstract 25) showed treatment with fulvestrant (FASLODEX) 500 mg reduced the risk of disease progression (assessed as time to progression (TTP)) by 20% (HR 0.80; 95% CI 0.68-0.94, p=0.006) when compared with fulvestrant 250 mg, the dose currently approved by the Food and Drug Administration (FDA). CONFIRM (COmparisoN of FASLODEX In Recurrent or Metastatic breast cancer) a double-blind, double-dummy study, evaluated the efficacy of fulvestrant 500 mg/month (n=362) compared with fulvestrant 250 mg/month (n=374) to treat postmenopausal women with hormone receptor-positive metastatic breast cancer who have progressed or recurred following prior endocrine therapy.(i)

(Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO )

"Findings from CONFIRM provide additional data showing that increasing the dose of fulvestrant from 250 mg to 500 mg may improve the effectiveness of a currently available treatment option to help maintain disease control longer -- a primary objective of treatment for women with metastatic breast cancer," said Dr. Angelo Di Leo, M.D., Ph.D, Head of Sandro Pitigliani Medical Oncology Unit, Hospital of Prato, Italy, and CONFIRM principal investigator.

Patients were randomized to receive either fulvestrant 500 mg (2 x 250 mg intramuscular injections) or fulvestrant 250 mg/month on days 0, 14 and 28, followed by 500 mg every 28 days thereafter. The primary objective was to compare the efficacy, as measu
'/>"/>

SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection
2. Lentigen Awarded Phase I SBIR Grant for Hepatitis C Vaccine
3. Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock
4. Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
5. Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium
6. Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia
7. Final Data from Phase 2 Study Confirm High Response Rate of Micromets Blinatumomab in Patients with Acute Lymphoblastic Leukemia
8. Hemodynamic Therapeutics Announces Successful Completion of Initial Phase 2 Clinical Study for Novel Combination Hypertension Therapy
9. Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
11. TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Calif. , Dec. 18, 2014  Sage ... new generation of equipment for the testing of ... release of the new Luminary™ Profiler, the industry,s ... light-based measurement in a cost-effective, portable unit. ... the specific needs of the cannabis industry, the ...
(Date:12/19/2014)... 18, 2014 Capnia, Inc. (NASDAQ: ... medical diagnostics based on its proprietary Sensalyze™ Technology ... announced financial results for the third quarter and ... "Following the completion of our initial public offering ... the recently initiated CoSense® commercial launch," said Anish ...
(Date:12/19/2014)... , Dec. 18, 2014 Baptist Health Lexington ... to receive full Atrial Fibrillation with Electrophysiology Services ... (SCPC). Atrial fibrillation is the most common cardiac ... in some cases can lead to stroke and possible death. ... States have atrial fibrillation and the numbers are ...
Breaking Medicine Technology:Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3
(Date:12/20/2014)... LunaDress has recently announced its 2015 collection of ... on all of its special occasion dresses & wedding apparel. ... wedding gown. If you have no idea of what to ... different wedding dress styles and our dress experts are here ... current special offer, up to 80% off," the CEO of ...
(Date:12/20/2014)... 20, 2014 (HealthDay News) -- The holidays can be ... contend with fresh trees, scented candles and other allergy ... the decorations that have been packed away in dank ... allergy and asthma patients," Dr. Rachna Shah, an affiliate ... Medicine, said in Loyola news release. Shah, who ...
(Date:12/20/2014)... December 20, 2014 Angeldress.co.uk, the distinguished ... great for worldwide dress fans. The company has recently ... and information. For the holiday season, Angeldress Blog ... special wedding apparel. , Angeldress.co.uk prides itself in offering ... level of service. All the company’s outfits are very ...
(Date:12/20/2014)... York, NY (PRWEB) December 20, 2014 The ... has caused quite a stir, not only in Hollywood, but ... on December 18th , the ripples of that attack are ... executives’ very jobs at risk. But they are not ... correspondences exposed could be in for some embarrassing times ahead, ...
(Date:12/20/2014)... 2014 Xarelto bleeding lawsuits filed ... uncontrollable bleeding and other serious side effects will be ... Louisiana for coordinated pretrial proceedings, Wright & Schulte LLC ... issued an order Friday to transfer 21 Xarelto lawsuits ... federal courts to the Louisiana district court for coordination ...
Breaking Medicine News(10 mins):Health News:2015 Collection of Wedding Dresses from LunaDress Online on Sale Now 2Health News:Holiday Trimmings Can Trigger Allergies 2Health News:Trendy Professional Wedding Apparel Recommended by Angeldress Blog 2Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 2Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 3Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 5Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 3Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 4
... 5 World-renowned heart,surgeon Dr. Rafael Espada has made ... Guatemala. President-elect Alvaro Colom, with Dr.,Espada as his running ... percent of the country,s votes. The two will take,office ... Espada has practiced for more than 30 years,as a ...
... for the NFL,s,Chicago Bears will visit hospitalized veterans Tuesday, ... as part of the Disabled American,Veterans (DAV) Celebrity Entertainment ... at 2:30 p.m., to honor,veterans for serving our nation ... the day for those who have sacrificed,so much for ...
... Launched Inpatient Certification ... ... Siemens Medical,Solutions (http://www.usa.siemens.com/healthcareit ) today announced that,Soarian(R) Clinicals ... pre-market, conditionally CCHIT Certified(sm),status from the Certification Commission for Healthcare ...
... attacks is best served by continuing to take prescribed ... had a heart attack stop taking these lifesaving medications ... Clinic study presented today at the American Heart Associations ... data also show that in the short term, smokers ...
... The American College of Physicians (ACP) today renewed its call ... Medicare reimbursements set to take effect Jan. 1 with at ... in a way that does not make the problem worse ... physicians, related subspecialists and medical students reacted to the final ...
... today launched its,new healthcare-focused Sovereign and Winston Series ... Limited at the Healthcare,Design.07 Conference. Charles Alan is ... nation, recognized not only for its product,line, but ... Winston,Series are available in the United States, Canada ...
Cached Medicine News:Health News:Houston Heart Surgeon Elected Vice President of Guatemala 2Health News:Siemens Medical Solutions Receives CCHIT Certification for Soarian Clinicals With Siemens Pharmacy and Med Administration Check 2Health News:Siemens Medical Solutions Receives CCHIT Certification for Soarian Clinicals With Siemens Pharmacy and Med Administration Check 3Health News:Siemens Medical Solutions Receives CCHIT Certification for Soarian Clinicals With Siemens Pharmacy and Med Administration Check 4Health News:Mayo Clinic study finds that after heart attack most patients stop taking life-saving drugs 2Health News:Congress called on to replace 'devastating' cuts in Medicare reimbursements by ACP 2Health News:Charles Alan Launches Healthcare-focused Furniture Lines with NuBax Seating Technology, Offering Smart Design and Health Benefits 2Health News:Charles Alan Launches Healthcare-focused Furniture Lines with NuBax Seating Technology, Offering Smart Design and Health Benefits 3Health News:Charles Alan Launches Healthcare-focused Furniture Lines with NuBax Seating Technology, Offering Smart Design and Health Benefits 4
... is designed to give accurate and ... neurosurgical intensive care, trauma, and operating ... and easy to use, and provides ... built-in audible alarm alerts attending staff ...
A portable, easy to use, dual-channel laser-Doppler tissue perfusion and temperature monitoring system, at a remarkably affordable price....
... highly featured laser doppler system for ... from multiple tissue sites. This latest ... Signal Processing (DSP) and laser Doppler ... simple to use, multi-channel monitor, setting ...
... highly featured laser doppler system for ... from multiple tissue sites. This latest ... Signal Processing (DSP) and laser Doppler ... simple to use, multi-channel monitor, setting ...
Medicine Products: